Last reviewed · How we verify
Indacaterol and Mometasone Furoate
Indacaterol and Mometasone Furoate is a Small molecule drug developed by Morten Hostrup, PhD. It is currently in Phase 1 development.
At a glance
| Generic name | Indacaterol and Mometasone Furoate |
|---|---|
| Sponsor | Morten Hostrup, PhD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Asthma
- Nasopharyngitis
- Bronchitis
- Upper respiratory tract infection
- Headache
- Pharyngitis
- Influenza
- Cough
- Dysphonia
- Rhinitis allergic
- Respiratory tract infection viral
- Viral upper respiratory tract infection
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma (PHASE3)
- A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®
- Role of Lung Function for Exercise Capacity in Well-trained Individuals (NA)
- A 24-week rPMS Study in Real-world Setting for Enerzair
- Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma (PHASE2)
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indacaterol and Mometasone Furoate CI brief — competitive landscape report
- Indacaterol and Mometasone Furoate updates RSS · CI watch RSS
- Morten Hostrup, PhD portfolio CI
Frequently asked questions about Indacaterol and Mometasone Furoate
What is Indacaterol and Mometasone Furoate?
Indacaterol and Mometasone Furoate is a Small molecule drug developed by Morten Hostrup, PhD.
Who makes Indacaterol and Mometasone Furoate?
Indacaterol and Mometasone Furoate is developed by Morten Hostrup, PhD (see full Morten Hostrup, PhD pipeline at /company/morten-hostrup-phd).
What development phase is Indacaterol and Mometasone Furoate in?
Indacaterol and Mometasone Furoate is in Phase 1.
What are the side effects of Indacaterol and Mometasone Furoate?
Common side effects of Indacaterol and Mometasone Furoate include Asthma, Nasopharyngitis, Bronchitis, Upper respiratory tract infection, Headache, Pharyngitis.